GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Notable Labs Ltd (NAS:NTBL) » Definitions » Capex-to-Revenue

Notable Labs (Notable Labs) Capex-to-Revenue : 0.21 (As of Dec. 2023)


View and export this data going back to 2023. Start your Free Trial

What is Notable Labs Capex-to-Revenue?

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue.

Notable Labs's Capital Expenditure for the six months ended in Dec. 2023 was $-0.07 Mil. Its Revenue for the six months ended in Dec. 2023 was $0.31 Mil.

Hence, Notable Labs's Capex-to-Revenue for the six months ended in Dec. 2023 was 0.21.


Notable Labs Capex-to-Revenue Historical Data

The historical data trend for Notable Labs's Capex-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Notable Labs Capex-to-Revenue Chart

Notable Labs Annual Data
Trend Dec21 Dec22 Dec23
Capex-to-Revenue
1.55 5.13 0.21

Notable Labs Semi-Annual Data
Dec21 Dec22 Dec23
Capex-to-Revenue 1.55 5.13 0.21

Competitive Comparison of Notable Labs's Capex-to-Revenue

For the Biotechnology subindustry, Notable Labs's Capex-to-Revenue, along with its competitors' market caps and Capex-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Notable Labs's Capex-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Notable Labs's Capex-to-Revenue distribution charts can be found below:

* The bar in red indicates where Notable Labs's Capex-to-Revenue falls into.



Notable Labs Capex-to-Revenue Calculation

Notable Labs's Capex-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (-0.065) / 0.31
=0.21

Notable Labs's Capex-to-Revenue for the quarter that ended in Dec. 2023 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (-0.065) / 0.31
=0.21

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Notable Labs  (NAS:NTBL) Capex-to-Revenue Explanation

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. The ratio shows how aggressively the company reinvests its revenue back into productive assets. However, a high ratio potentially indicates that the company has invested too much in innovation and infrastructure, taking up funds that could be used to boost productivity and increase revenue. Therefore, a high Capex to Revenue Ratio could be a positive or a negative sign depending on how effectively a company converts those investments into future earnings.


Notable Labs Capex-to-Revenue Related Terms

Thank you for viewing the detailed overview of Notable Labs's Capex-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Notable Labs (Notable Labs) Business Description

Traded in Other Exchanges
N/A
Address
320 Hatch Drive, Foster City, CA, USA, 94404
Notable Labs Ltd is a clinical-stage platform therapeutics company developing predictive precision medicines for patients with cancer. Through its proprietary Predictive Precision Medicines Platform (PPMP), Notable bio-simulates a cancer treatment to predict whether or not a patient is likely to respond to that specific therapeutic. Through its proprietary Predictive Precision Medicines Platform (PPMP), Notable bio-simulates a cancer treatment to predict whether or not a patient is likely to respond to that specific therapeutic.